C‑C motif chemokine receptors in gastric cancer (Review)
- Authors:
- Hyewon Ryu
- Seung Woo Baek
- Ji Young Moon
- In‑Sook Jo
- Nayoung Kim
- Hyo Jin Lee
-
Affiliations: Department of Internal Medicine, Chungnam National University Hospital, Daejeon 35015, Republic of Korea, Department of Medical Science, School of Medicine Chungnam National University and Chungnam National University Hospital, Daejeon 35015, Republic of Korea, Department of Internal Medicine, School of Medicine Chungnam National University and Chungnam National University Hospital, Daejeon 35015, Republic of Korea - Published online on: October 27, 2017 https://doi.org/10.3892/mco.2017.1470
- Pages: 3-8
This article is mentioned in:
Abstract
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S: CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting. World J Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C, Shen H, et al: Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tan P and Yeoh KG: Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology. 149:1153–1162.e3. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ang YL, Yong WP and Tan P: Translating gastric cancer genomics into targeted therapies. Crit Rev Oncol Hematol. 100:141–146. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Grabsch HI and Tan P: Gastric cancer pathology and underlying molecular mechanisms. Dig Surg. 30:150–158. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Necula LG, Mambet C, Albulescu R and Diaconu CC: Epigenetics in gastric carcinogenesis: TET genes as important players. J Immunoassay Immunochem. 36:445–455. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Thiel A and Ristimäki A: Targeted therapy in gastric cancer. APMIS. 123:365–372. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ, Ryu H, Choi YS, Song IC, Yun HJ, Jo DY and Kim S: Just toxicity, or toxicity as a biomarker of efficacy of ramucirumab in breast cancer? J Clin Oncol. 33:27122015. View Article : Google Scholar : PubMed/NCBI | |
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yun HJ, Ryu H, Choi YS, Song IC, Jo DY, Kim S and Lee HJ: C-X-C motif receptor 7 in gastrointestinal cancer. Oncol Lett. 10:1227–1232. 2015.PubMed/NCBI | |
|
Mburu YK, Wang J, Wood MA, Walker WH and Ferris RL: CCR7 mediates inflammation-associated tumor progression. Immunol Res. 36:61–72. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kunkel SL, Strieter RM, Lindley IJ and Westwick J: Chemokines: New ligands, receptors and activities. Immunol Today. 16:559–561. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, et al: International union of basic and clinical pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 66:1–79. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P and Lesniak MS: Chemokines in tumor progression and metastasis. Oncotarget. 4:2171–2185. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Arya M, Patel HR and Williamson M: Chemokines: Key players in cancer. Curr Med Res Opin. 19:557–564. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Verbeke H, Struyf S, Laureys G and Van Damme J: The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Verbeke H, Geboes K, Van Damme J and Struyf S: The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta. 1825:117–129. 2012.PubMed/NCBI | |
|
Luster AD: Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 338:436–445. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ali S and Lazennec G: Chemokines: Novel targets for breast cancer metastasis. Cancer Metastasis Rev. 26:401–420. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Weitzenfeld P and Ben-Baruch A: The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 352:36–53. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vandercappellen J, Van Damme J and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tazzyman S, Lewis CE and Murdoch C: Neutrophils: Key mediators of tumour angiogenesis. Int J Exp Pathol. 90:222–231. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 270:27348–27357. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Strieter RM, Burdick MD, Gomperts BN, Belperio JA and Keane MP: CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16:593–609. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Arima H, Hirata M, Ishigami S and Aikou T: CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer. Int J Oncol. 35:19–24. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Deguchi K, Ichikawa D, Soga K, Watanabe K, Kosuga T, Takeshita H, Konishi H, Morimura R, Tsujiura M, Komatsu S, et al: Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res. 30:2361–2366. 2010.PubMed/NCBI | |
|
Ishigami S, Natsugoe S, Nakajo A, Tokuda K, Uenosono Y, Arigami T, Matsumoto M, Okumura H, Hokita S and Aikou T: Prognostic value of CCR7 expression in gastric cancer. Hepatogastroenterology. 54:1025–1028. 2007.PubMed/NCBI | |
|
Kwak MK, Hur K, Park DJ, Lee HJ, Lee HS, Kim WH, Lee KU, Choe KJ and Yang HK: Expression of chemokine receptors in human gastric cancer. Tumour Biol. 26:65–70. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mashino K, Sadanaga N, Yamaguchi H, Tanaka F, Ohta M, Shibuta K, Inoue H and Mori M: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62:2937–2941. 2002.PubMed/NCBI | |
|
Wang WN, Chen Y, Zhang YD and Hu TH: The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer. Tumour Biol. 34:1865–1871. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yan C, Zhu ZG, Yu YY, Ji J, Zhang Y, Ji YB, Yan M, Chen J, Liu BY, Yin HR and Lin YZ: Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol. 10:783–790. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou S, Shen Z, Wang Y, Ma H, Xu S, Qin J, Chen L, Tao H, Zhen Z, Chen G, et al: CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 8:e744302013. View Article : Google Scholar : PubMed/NCBI | |
|
Schmausser B, Endrich S, Brändlein S, Schär J, Beier D, Müller-Hermelink HK and Eck M: The chemokine receptor CCR7 is expressed on epithelium of non-inflamed gastric mucosa, Helicobacter pylori gastritis, gastric carcinoma and its precursor lesions and up-regulated by H. pylori. Clin Exp Immunol. 139:323–327. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chang WJ, Du Y, Zhao X, Ma LY and Cao GW: Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pituch-Noworolska A, Drabik G, Szatanek R, Białas M, Kołodziejczyk P, Szczepanik A, Stachura J and Zembala M: Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer. Pol J Pathol. 58:93–97. 2007.PubMed/NCBI | |
|
Chen J, Yang J, Jiang J, Zhuang Y and He W: Function and subsets of dendritic cells and natural killer cells were decreased in gastric cancer. Int J Clin Exp Pathol. 7:8304–8311. 2014.PubMed/NCBI | |
|
Mégraud F, Bessède E and Varon C: Helicobacter pylori infection and gastric carcinoma. Clin Microbiol Infect. 21:984–990. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fehlings M, Drobbe L, Moos V, Viveros P Renner, Hagen J, Beigier-Bompadre M, Pang E, Belogolova E, Churin Y, Schneider T, et al: Comparative analysis of the interaction of Helicobacter pylori with human dendritic cells, macrophages, and monocytes. Infect Immun. 80:2724–2734. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Moschovakis GL and Förster R: Multifaceted activities of CCR7 regulate T-cell homeostasis in health and disease. Eur J Immunol. 42:1949–1955. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Raju R, Gadakh S, Gopal P, George B, Advani J, Soman S, Prasad TS and Girijadevi R: Differential ligand-signaling network of CCL19/CCL21-CCR7 system. Database (Oxford). 2015:pii: bav1062015. View Article : Google Scholar | |
|
Kodama J, Hasengaowa, Seki N, Kusumoto T and Hiramatsu Y: Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol. 28:370–375. 2007.PubMed/NCBI | |
|
Zhang J, Zhou Y and Yang Y: CCR7 pathway induces epithelial-mesenchymal transition through up-regulation of Snail signaling in gastric cancer. Med Oncol. 32:4672015.PubMed/NCBI | |
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X, Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced epithelial-mesenchymal transition and is associated with lymph node metastasis and poor overall survival in gastric cancer. Oncotarget. 6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sallusto F and Baggiolini M: Chemokines and leukocyte traffic. Nat Immunol. 9:949–952. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hughes A and Nelson M: HIV entry: New insights and implications for patient management. Curr Opin Infect Dis. 22:35–42. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Soria G and Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lazennec G and Richmond A: Chemokines and chemokine receptors: New insights into cancer-related inflammation. Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
González-Martín A, Gómez L, Lustgarten J, Mira E and Mañes S: Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res. 71:5455–5466. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
González-Martin A, Mira E and Mañes S: CCR5 as a potential target in cancer therapy: Inhibition or stimulation? Anticancer Agents Med Chem. 12:1045–1057. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R, Yuan S and Zhang L: Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia. Cancer Sci. 103:904–912. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hartmann MC, Dwyer RM, Costello M, Potter SM, Curran C, Hennessy E, Newell J, Griffin DG and Kerin MJ: Relationship between CCL5 and transforming growth factor-β1 (TGFβ1) in breast cancer. Eur J Cancer. 47:1669–1675. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L and Sun S: Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep. 21:1113–1121. 2009.PubMed/NCBI | |
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y and Abe A: Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 7:285–289. 2001.PubMed/NCBI | |
|
Yaal-Hahoshen N, Shina S, Leider-Trejo L, Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 12:4474–4480. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Z, Xu X, Luo X, Li L, Huang B, Li X, Tao D, Hu J and Gong J: Role of RANTES and its receptor in gastric cancer metastasis. J Huazhong Univ Sci Technolog Med Sci. 31:342–347. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin SS, Fan W, Sun L, Li FF, Zhao RP, Zhang LY, Yu BY and Yuan ST: The saponin DT-13 inhibits gastric cancer cell migration through down-regulation of CCR5-CCL5 axis. Chin J Nat Med. 12:833–840. 2014.PubMed/NCBI | |
|
Mencarelli A, Graziosi L, Renga B, Cipriani S, D'Amore C, Francisci D, Bruno A, Baldelli F, Donini A and Fiorucci S: CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 6:784–793. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sugasawa H, Ichikura T, Tsujimoto H, Kinoshita M, Morita D, Ono S, Chochi K, Tsuda H, Seki S and Mochizuki H: Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric cancer. J Surg Oncol. 97:445–450. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gawron AJ, Fought AJ, Lissowska J, Ye W, Zhang X, Chow WH, Freeman LE Beane and Hou L: Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand J Gastroenterol. 46:333–340. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ding H, Zhao L, Dai S, Li L, Wang F and Shan B: CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer. Biomed Pharmacother. 77:142–149. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Okita K, Furuhata T, Kimura Y, Kawakami M, Yamaguchi K, Tsuruma T, Zembutsu H and Hirata K: The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression. J Exp Clin Cancer Res. 24:439–446. 2005.PubMed/NCBI | |
|
Shi M, Chen D, Yang D and Liu XY: CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1. J Exp Clin Cancer Res. 34:1492015. View Article : Google Scholar : PubMed/NCBI | |
|
Alfonso-Pérez M, López-Giral S, Quintana NE, Loscertales J, Martín-Jiménez P and Muñoz C: Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol. 79:1157–1165. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Cuesta-Mateos C, Loscertales J, Kreutzman A, Colom-Fernández B, Portero-Sáinz I, Pérez-Villar JJ, Terrón F and Muñoz-Calleja C: Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunol Immunother. 64:665–676. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Somovilla-Crespo B, Alfonso-Pérez M, Cuesta-Mateos C, Carballo-de Dios C, Beltrán AE, Terrón F, Pérez-Villar JJ, Gamallo-Amat C, Pérez-Chacón G, Fernández-Ruiz E, et al: Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma. J Hematol Oncol. 6:892013. View Article : Google Scholar : PubMed/NCBI | |
|
Boyle ST, Ingman WV, Poltavets V, Faulkner JW, Whitfield RJ, McColl SR and Kochetkova M: The chemokine receptor CCR7 promotes mammary tumorigenesis through amplification of stem-like cells. Oncogene. 35:105–115. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ and Chun KH: MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 14:R142012. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan J, Ji J, Song H, Qian Q, Wang K, Wang C and Cui D: Fluorescent magnetic nanoparticle-labeled mesenchymal stem cells for targeted imaging and hyperthermia therapy of in vivo gastric cancer. Nanoscale Res Lett. 7:3092012. View Article : Google Scholar : PubMed/NCBI | |
|
Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H and Schmid-Alliana A: CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One. 6:e288422011. View Article : Google Scholar : PubMed/NCBI | |
|
Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Velasco-Velázquez M, Xolalpa W and Pestell RG: The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets. 18:1265–1275. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Che LF, Shao SF and Wang LX: Downregulation of CCR5 inhibits the proliferation and invasion of cervical cancer cells and is regulated by microRNA-107. Exp Ther Med. 11:503–509. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maeda K, Das D, Nakata H and Mitsuya H: CCR5 inhibitors: Emergence, success, and challenges. Expert Opin Emerg Drugs. 17:135–145. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ochoa-Callejero L, Pérez-Martínez L, Rubio-Mediavilla S, Oteo JA, Martínez A and Blanco JR: Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One. 8:e539922013. View Article : Google Scholar : PubMed/NCBI | |
|
Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS and Linehan DC: Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 182:1746–1755. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 63:8360–8365. 2003.PubMed/NCBI | |
|
Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, et al: Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Mol Cancer Ther. 6:2948–2958. 2007. View Article : Google Scholar : PubMed/NCBI |
